Kitano E, Kitamura H, Furue M, Harada M: Molecular analysis of a novel hereditary C3 deficiency with systemic lupus erythematosus. Biochim Biophysica Res Commun 330:298-304,2005

27) Karube K, Oshima K, Tsuchiya T, Yamaguchi T, Kawano R, Suzumiya J, Harada M, Kikuchi M: A "floral" variant of nodal marginal zone lymphoma. Human Pathology 36:202-206,2005

28) Okamura J, Utsunomiya A, Tanosaki R, Uike N, Sonoda S, Kannagi M, Tomonaga M, Harada M, Kimura N, Masuda M, Kawano F, Yufu Y, Hattori H, Kikuchi H, Saburi Y: Allogeneic stem-cell transplantation with reduced conditioning T-cell leukemia/lymphoma. Blood 105: 4143-4145, 2005

29) Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, Watanabe T, Akashi K, Shultz LD, Harada M: Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ hain^{nuU} mice. Blood 106: 1565 - 1573,2005

30) Kakumitsu H, Kamezaki K, Shimoda K, Karube K, Haro T, Numata A, Shide K, Matsuda T, Oshima K, Harada M: Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leuk Res 29:761-769,2005

31) Numata A, Shiomoda K, Kamezaki K, Haro T, Kakumitsu H, Shide K, Kato K, Miyamoto T, Yamashita Y, Oshima Y, Nakajima H, Iwama A, Aoki K, Takase K, Gondo H, Mano H, Harada M: Signal transducers and activators of transcription 3 augments the transcriptional activity of CCAAT/Enhancer-binding protein α in granulocyte colony-stimulating factor signaling pathway. J Biol Chem 280:12621-12629,2005

32) Kawano N, Ishikawa F, Shimoda K, Yasukawa M, Nagafuji K, Miyamoto T, Baba E, Tanaka T, Yamasaki S, Gondo H, Otsuka T, Ohsima K, Shultz LD, Akashi K, Harada M: Efficient engraftment of primary adult T-cell leukemia cells in newborn NOD/SC1D/β 2-microglobulin^{null} mice. Leukemia 19:1384-1390,2005

33) Yokoyama T, Okamura S, Asano Y, Kamezaki K, Numata A, Kakumitsu H, Shide K, Nakashima H, Kanaji T, Sekine Y, Mizuno Y, Okamura J, Matsuda T, Harada M, Niho Y, Shimoda K:A novel mutation in the juxtamembrane intracellular sequence of the granulocyte colony-stimulating factor(G-CSF) receptor gene in a patient with severe congenital neutropenia augments G-CSF proliferation activity but not through the MAP kinase cascade. Int J Hematol 82:28-34,2005

34) Imamura R, Miyamoto T, Yoshimioto G, Kamezaki K, Ishikawa F, Henzan H, Kato K, Takase K, Numata A, Nagafuji K, Okamura T, Sata M, Harada M, Inaba S: Mobilization of human lymphoid progenitors after treatment with granulocyte clolony-stimulating factor. J Immunol 175:2647-2654,2005

35) Yoshida S, Ishikawa F, Shimoda K, Nagafuchi S, Shimoda S,Yasukawa M, Kanemaru T, Ishibashi H, Shultz LD, Harada M: Human Cord Blood-derived Cells Generate Insulin-Producing Cells In Vivo Stem Cells (in press)

36) Matsuoka K, Ichinohe T, Hashimoto D, Asakura S, Tanimoto M, Teshima T.: Fetal tolerance to maternal antigens improves the outcome of allogeneic bone marrow transplantation by a $CD4^{+}CD25^{+}$ T-cell-dependent mechanism. Blood. 107:404-409. 2006

37) Ichinohe T, Teshima T, Matsuoka K, Maruya E, Saji H.: Fetal-maternal microchimerism: impact on hematopoietic

stem cell transplantation. Curr Opin Immunol. 17:546-552.2005;

38) Kodera Y, Nishida T, Ichinohe T, Saji H.: Human leukocyte antigen haploidentical hematopoietic stem cell transplantation: indications and tentative outcomes in Japan. Semin Hematol. 42:112-118. 2005

39) Narimatsu H, Wake A, Miura Y, Tanaka H, Matsumura T, Takagi S, Kato D, Myojo T, Kusumi E, Masuoka K, Miyakoshi K, Morinaga S, Hiroh S, Ichinohe T, Taniguchi S.: Successful engraftment in crossmatch-positive HLA- mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusion. Bone Marrow Transplant. 36:555-556. 2005

40) Kojima R, Kami M, Kanda Y, Kusumi E, Kishi Y, Tanaka Y, Yoshioka S, Morishima S, Fujisawa S, Mori S, Kasai M, Hatanaka K, Tajima K, Kasai M, Mitani K, Ichinohe T, Hirai H, Taniguchi S, Sakamaki H, Harada M, Takaue Y.: Comparison between reduced-intensity and conventional myelo-ablative allogeneic stem-cell trans-plantation in patients with hematologic malignancies aged between 50 and 59. Bone Marrow Transplant. 36:667-674. 2005

41) Tsuji Y. Ito S. Isoda T. Kajiwara M. Nagasawa M. Morio T. Mizutani S. Successful nonmyeloablative cord blood transplantation for an infant with malignant infantile osteopetrosis. J. Pediatr. Hematol. Oncol. 27: 495-498. 2005

42) Okano M. Kawa K. Kimura H. Yachie A. Wakiguchi H. Maeda A. Imai S. Ohga S. Kanegane H. Tsuchiya S. Morio T. Mori M. Yokota S. Imashuku S. Proposed Guidelines for Diagnosing Chronic Active Epstein-Barr Virus Infection. Am. J. Hematol. 80: 64-69. 2005

43) Yu JH. Lim JW. Kim KH. Morio T. Kim H. NADPH oxidase and apoptosis in cerulein-stimulated pancreatic acinar AR42J cells. Free Radic Biol Med. 39: 590-602. 2005

44) Imai K. Zhu Y. Revy P. Morio T. Mizutani S. Fischer A. Nonoyama S. Durandy A. Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2. Clin. Immunol. 115: 277-85. 2005

45) Chen L, Morio T, Minegishi Y, Nakada S, Nagasawa M, Komatsu K, Chessa L, Villa A, Lecis D, Delia D, Mizutani S. Ataxia-telangiectasia-mutated dependent phosphorylation of Artemis in response to DNA damage. Cancer Sci. 96 (2):134-41. 2005

46) Tomizawa D. Aoki Y. Nagasawa M. Kajiwara M. Sekine T. Shimizu N. Kato M. Yachie A. Mizutani S. Morio T. Adopted immunotherapy for mixed chimerism after unrelated cord blood transplantation using reduced-intensity conditioning in Omenn disease. Eur. J. Haematol. 75: 441-444. 2005

47) Nagasawa M, Zhu Y, Isoda T, Tomizawa D, Itoh S, Kajiwara M, Morio T, Nonoyama S, Shimizu N, Mizutani S. Analysis of serum soluble CD40 ligand (sCD40L) in the patients undergoing allogeneic stem cell transplantation: Platelet is a major source of serum sCD40L Eur. J. Hematol. 74:54-60. 2005

48) Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies. Eur J Immunol. 36(3):593-602. 2006.3

49) Terakura S, Murata M, Nishida T, Emi N, Akatsuka Y, Morishima Y, Kodera Y, Naoe T. Increased risk for treatment-related mortality after bone marrow transplantation in GSTM1-positive recipients. Bone Marrow Transplant.;37(4):381-386. 2006.2

50) Ito Y, Kondo E, Demachi-Okamura A, Akatsuka Y, Tsujimura K, Tanimoto M, Morishima Y, Takahashi T, Kuzushima K. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation. J Virol.;80(2):883-890. 2006.1

51) Terakura S, Murata M, Nishida T, Emi N, Akatsuka Y, Riddell SR, Morishima Y, Kodera Y, Naoe T. A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. Br J Haematol. 129(2):221-228. 2005.4

52) Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, Ogawa S. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65:6071-6079, 2005.

53) Kawazu M, Asai T, Ichikawa M, Yamamoto G, Saito T, Goyama S, Mitani K, Miyazono K, Chiba S, Ogawa S, Kurokawa M, Hirai H. Functional Domains of Runx1 Are Differentially Required for CD4 Repression, TCRβExpression, and CD4/8 Double-Negative to CD4/8 Double-Positive Transition in Thymocyte Development. J Immunol: 174, 3526-3533, 2005.

54) Suzuki Y, Adachi Y, Minamino K, Zhang Y, Iwasaki M, Nakano K, Koike Y, and Ikehara S: A new strategy for treatment of malignant tumor: Intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion. Stem Cells. 23:365-370.2005

55) Minamino K, Adachi Y, Okigaki M, Ito H, Togawa Y, Fujita K, Tomita M, Suzuki Y, Zhang Y, Iwasaki M, Nakano K, Koike Y, Matsubara H, Iwasaki T, Matsumura M, and Ikehara S: Macrophage colony-stimulating factor (M-CSF), as well as granulocyte colony-stimulating factor (G-CSF), accelerates nevascularization. Stem cell. 23:347-354.2005

56) Iwasaki M, Adachi Y, Minamino K, Suzuki Y, Zhang Y, Okigaki M, Nakano K, Taketani S, Takahashi H, Iwasaka T, and Ikehara S: Mobilization of bone marrow cells by G-CSF rescues mice from cisplatin-induced renal failure, and M-CSF enhances the effects of G-CSF. J. Am. Soc. Nephrol. 16:658-666.2005

57) Taira M, Inaba M, Takada K, Baba S, Fukui J, Ueda Y, Kwoh AH, Hisha H, Kamiyama Y, and Ikehara S: Treatment of streptozotocin-induced disease mellitus in rats by transplantation of islet cells from two major histocompatibility comples disparate rats in combination with intra bone marrow injection of allogeneic bone marrow cells. Transplantation. 79:680-687.2005

58) Kaneda H, Adachi Y, Saito Y, Ikebukuro K, Machida H, Suzuki Y, Minamino K, Zhang Y, Iwasaki M, Imamura H, and Ikehara S: Long-term observation after simultaneous lung and intra-bone marrow-bone marrow transplantation. J. Heart Lung Transplant. 24:1415-1423,2005

59) Wang X, Hisha H, Taketani S, Inaba M, Li Q, Cui W, Song C, Fan T, Cui Y, Guo K, Yang G, Fan H, Lian Z, Gershwin ME, and Ikehara S: Neural cell adhesion molecule contributes to hemopoiesis-supporting capacity of stromal cell lines. Stem Cells. 23:1389-1399.2005

60) Iwasaki M, Adachi Y, Nishiue T, Minamino K, Suzuki Y, Zhang Y, Nakano K, Koike Y, Wang J, Mukaide H, Taketani S, Yuasa F, Tsubouchi H, Gohda E, Iwasaka T, and Ikehara S: Hepatocyte growth factor delivered by ultrasound-mediated destruction of microbubbles induces proliferation of cardiomyocytes and amelioration of left ventricle contractile function in doxorubicin-induced cardiomyopathy. Stem Cells. 23:1588-1597.2005

61) Wang X, Hisha H, Taketani S, Adachi Y, Li Q, Cui W, Cui Y, Wang J, Song C, Mizokami T, Okazaki S, Fan T, Fan H, Lian Z, Gershwin ME, and Ikehara S: Characterization of mesenchymal stem cells isolated from mouse fetal bone marrow. Stem Cells. In press

62) Takada K, Inaba M, Ichioka N, Ueda Y, Taira M, Baba S, Mizokami T, Wang X, Hisha H, Iida H, and Ikehara S: Treatment of senile osteoporosisi in SAMP6 mice by intra-bone marrow injection of allogeneic bone marrow cells. Stem Cells. 24:399-405.2006

63) Nakano K, Adachi Y, Minamino K, Iwasaki M, Shigematsu A, Kirivama N, Suzuki Y, Koike Y, Mukaide H, Taniuchi S, Kobayashi Y, Kaneko K, and Ikehara S: Mechanisms underlying acceleration of blood flow recovery in ischemic limbs by macrophage colony-stimulating factor (M-CSF). Stem Cells. In press

64) Ikehara S :Intra-bone marrow-Bone marrow transplantation. Ann. N. Y. Acad. Sci. 1051:1-9.2005

65) Ikehara S: A new bone marrow transplantation method for the prevention of graft-versus-host disease. Curr. Med. Chem., Endoc. & Metab. Agents. 5:547-554.2005

66) Imamura M, Asano S, Harada M, Ikeda Y, Kato K, Kato S, Kawa K, Kojima S, Morishima Y, Morishita Y, Nakahata T, Okamura J, Okamoto S, Shiobara S, Tanimoto M, Tsuchida M, Atsuta Y, Yamamoto K, Tanaka J, Hamajima N, Kodera Y. Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan. Int J Hematol. 83(2):164-178. 2006.2

67) Oshiro A, Tagawa H, Ohshima K, Karube K, Uike N, Tashiro Y, Utsunomiya A, Masuda M, Takasu N, Nakamura S, Morishima Y, Seto M. Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood. 16:[Epub ahead of print] .2006.2

68) Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies. Eur J Immunol. 36(3):593-602. 2006.3

69) Terakura S, Murata M, Nishida T, Emi N, Akatsuka Y, Morishima Y, Kodera Y, Naoe T. Increased risk for treatment-related mortality after bone marrow transplantation in GSTM1-positive recipients. Bone Marrow Transplant. 37(4):381-386. 2006.2

70) Atsuta Y, Suzuki R, Yamamoto K, Terakura S, Iida H, Kohno A, Naoe T, Yano K, Wakita A, Taji H, Hamaguchi M, Kodera Y, Sao H, Morishima Y, Hamajima N, Morishita Y. Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation. Bone Marrow Transplant. 37(3):289-96. 2006.2

71) Suzuki T, Matsuo K, Ito H, Hirose K, Wakai K, Saito T, Sato S, Morishima Y, Nakamura S, Ueda R, Tajima K. A past history of gastric ulcers and Helicobacter

pylori infection increase the risk of gastric malignant lymphoma. Carcinogenesis. 7; [Epub ahead of print] 2006.1

72) Ito Y, Kondo E, Demachi-Okamura A, Akatsuka Y, Tsujimura K, Tanimoto M, Morishima Y, Takahashi T, Kuzushima K. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation. J Virol. 80(2):883-890. 2006.1

73) Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K, Minami H, Utsunomiya A, Taniwaki M, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Seriu T, Hotta T. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. J Clin Oncol. 24(1):174-180.2006.1

74) Kasugai Y, Tagawa H, Kameoka Y, Morishima Y, Nakamura S, Seto M. Identification of CCND3 and BYSL as candidate targets for the 6p21 amplification in diffuse large B-cell lymphoma. Clin Cancer Res. 11(23):8265-8272. 2005.12

75) Ogawa Y, Hotta T, Tobinai K, Watanabe T, Sasaki Y, Minami H, Morishima Y, Ogura M, Seriu T. Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. Ann Oncol. 17(2):330-3. 2006.2

76) Kanda Y, Sakamaki H, Sao H, Okamoto S, Kodera Y, Tanosaki R, Kasai M, Hiraoka A, Takahashi S, Miyawaki S, Kawase T, Morishima Y, Kato S; Japan Marrow Donor Program. Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor. Biol Blood Marrow Transplant. 11(11):881-889. 2005 11

77) Shimada K, Yokozawa T, Atsuta Y, Kohno A, Maruyama F, Yano K, Taji H, Kitaori K, Goto S, Iida H, Morishima Y, Kodera Y, Naoe T, Morishita Y. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplant. 36(2):115-121. 2005.7

78) Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, Ohshima K, Okamoto M, Morishima Y, Nakamura S, Seto M. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood. 106(5):1770-1777. 2005.9

79) Terakura S, Murata M, Nishida T, Emi N, Akatsuka Y, Riddell SR, Morishima Y, Kodera Y, Naoe T. A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. Br J Haematol. 129(2):221-8. 2005.4

80) Imai Y, Chou T, Tobinai K, Tanosaki R, Morishima Y, Ogura M, Shimazaki C, Taniwaki M, Hiraoka A, Tanimoto M, Koike T, Kogawa K, Hirai H, Yoshida T, Tamura K, Kishi K, Hotta T; CliniMACS Study Group. Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): results of Japanese phase II study. Bone Marrow Transplant. 35(5):479-487. 2005.3

81) Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A, Morishima Y, Nakamura S, Seto M. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene. 24(8):1348-58. 2005 2

82) Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA,

Geraghty DE, Hansen JA, Hurley CK, Mach B, Mayr WR, Parham P, Petersdorf EW, Sasazuki T, Schreuder GM, Strominger JL, Svejgaard A, Terasaki PI, Trowsdale J. Nomenclature for Factors of the HLA System, 2004. Hum Immunol. 66 (5): 571-636. 2005 5

83) Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Geraghty DE, Hansen JA, Hurley CK, Mach B, Mayr WR, Parham P, Petersdorf EW, Sasazuki T, Schreuder GM, Strominger JL, Svejgaard A, Terasaki PI, Trowsdale J. Nomenclature for factors of the HLA system, 2004. Tissue Antigens. 65 (4): 301-369. 2005 4

84) Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Geraghty DE, Hansen JA, Hurley CK, Mach B, Mayr WR, Parham P, Petersdorf EW, Sasazuki T, Schreuder GM, Strominger JL, Svejgaard A, Terasaki PI, Trowsdale J. Nomenclature for factors of the HLA system, 2004. Int J Immunogenet. 32 (2): 107-159. 2005 4

85) Kochi Y, Yamada R, Suzuki A, Harley JB, Shirasawa S, Sawada T, Bae SC, Tokuhiro S, Chang X, Sekine A, Takahashi A, Tsunoda T, Ohnishi Y, Kaufman KM, Kang CP, Kang C, Otsubo S, Yumura W, Mimori A, Koike T, Nakamura Y, Sasazuki T, Yamamoto K. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat Genet. 37 (5): 478-485. 2005 5

86) Onizuka M, Kasai M, Oba T, Atsuta Y, Terakura S, Suzuki R, Kitaori K, Miyamura K, Hotta T and Kodera Y. Increased frequency of the angiotensin-converting enzyme gene D-allele is associated with non-infectious pulmonary dysfunction following allogeneic stem cell transplant. 36:617-620.2005

87) 鬼塚真仁、吉川枝里、猪子英俊. 臓器移植と HLA タイピング. 日本臨床. 63(11):1945.2005

88) 鬼塚真仁、成瀬妙子、猪子英俊. 臓器移植と HLA. 日本臨床. 日本臨床. 63(4):653.2005

89) Miyashita R, Tsuchiya N, Yabe T, Kobayashi S, Hashimoto H, Ozaki S, and Tokunaga K. Association of killer cell immunoglobulin-like receptor genotypes with microscopic polyangiitis. Arthritis and Rheumatism. 54(3):992-7.2006

90) Hirayasu K, Ohashi J, Kashiwase K, Takanashi M, Satake M, Tokunaga K, and Yabe T. Long-term persistence of both functional and non-functional alleles at the leukocyte immunoglobulin-like receptor A3 (LILRA3) locus suggests balancing selection. Human Genetics. (in press). 2006

91) Murata M, Emi N, Izumisawa Y, Inaki A, Saitoh M, Naoe T.: Identification and frequency of a new HLA-A allele, A*030104. Tissue Antigens. 65 (4): 391-392.2005

92) Terakura S, Murata M, Nishida T, Emi N, Akatsuka Y, Riddell SR, Morishima Y, Kodera Y, Naoe T.: A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. Br J Haematol. 129 (2):221-228.2005

93) Terakura S, Murata M, Nishida T, Emi N, Akatsuka Y, Morishima Y, Kodera Y, Naoe T.: Increased risk for treatment-related mortality after marrow bone transplantation in GSTM1-positive recipients. Bone Marrow Transplant. 37 (4): 381-386.2006

94) Hishida A, Terakura S, Emi N, Yamamoto K, Murata M, Nishio K, Sekido Y, Niwa T, Hamajima N, Naoe T. : GSTT1 and GSTM1 deletions, NQO1 C609T polymorphism and risk of chronic myelogenous leukemia in

Japanese. Asian Pac J Cancer Prev. 6(3): 251-255.2005

95) Kanda Y, Sakamaki H, Sao H, Okimoto S, Kodera Y, Tanosaki R, Kasai M, Hiraoka A, Takahashi S, Miyawaki S, Kawase T, Morishima Y, Kato S; Japan Marrow Donor Program.: Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor. Biol Blood Marrow Transplant. 11(11): 881-9, 2005

96) Suzuki Y, Takemoto Y, Shimozawa N, Imanaka T, Kato S, Furuya H, Kaga M, Kato K, Hashimoto N, Onodera O, Tsuji S: Natural history of X-linked adrenoleukodystrophy in Japan. Brain & Development 27: 353-7, 2005

97) Kato S: Cord blood transplantation and cord blood banking. Hematology 10: 113-4, 2005

98) Yabe H, Hattori K, Inoue H, Matsumoto M, Hamanoue S, Hiroi A, Koike T, Kato S, Shimamura K, Yabe M: Fatal adenovirus infection indistinguishable from thrombotic microangiopathy after allogeneic CD34+ peripheral progenitor cell transplantation. Tokai J Exp Clin Med. 30(1): 71-75, 2005

99) Yabe H, Yabe M, Hattori K, Inoue H, Matsumoto M, Hamanoue S, Hiroi A, Koike T, Kato S: Secondary G-CSF mobilized blood stem cell transplantation without preconditioning in a patient with Gaucher disease: Report of a new approach which resulted incomplete reversal of severeskeletal involvement. Tokai J Exp Clin Med. 30(1): 77-82, 2005

100) Tsuboi K, Kawada H, Toh E, Lee YH, Tsuma M, Nakamura Y, Sato T, Ando K, Mochida J, Kato S, Hotta T: Potential and origin of the hematopoietic population in human skeletal muscle. Leuk Res. 29(3): 317-24, 2005

101) Nakai K, Kanda Y, Fukuhara S, Sakamaki H, Okamoto S, Kodera Y, Tanosaki R, Takahashi S, Matsushima T, Atsuta Y, Hamajima N, Kasai M, Kato S: Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodys-plastic syndrome. Leukemia 19(3): 396-401, 2005

102) Imamura M, Asano S, Harada M, Ikeda Y, Kato K, Kato S, Kawa K, Kojima S, Morishima Y, Morishita Y, Nakahata T, Okamura J, Okamoto S, Shiobara S, Tanimoto M, Tsuchida M, Atsuta Y, Yamamoto K, Tanaka J, Hamajima N, Kodera Y: Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan. International Journal of Hematology 83(2): 164-78, 2006

103) Muguruma Y, Yahata T, Miyatake H, Sato T, Uno T, Itoh J, Kato S, Ito M, Hotta T, Ando K: Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment. Blood 107(5): 1878-87, 2006

104) Ando K, Yahata T, Sato T, Miyatake H, Matsuzawa H, Oki M, Miyoshi H, Tsuji T, Kato S, Hotta T: Direct evidence for ex vivo expansion of human hematopoietic stem cells. Blood, Epub ahead of print, 2006

105) 加藤 俊一：小児造血幹細胞移植とシクロスポリン、免疫の進化—シクロスポリン20年の軌跡、医薬ジャーナル社、東京、126-133、2006

106) Suzuki T, Kyoi H,Ozeki K, Tomita A, Yamaji S,Suzuki R, Kodera Y,Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Kinoshita T, Emi N, Naoe T: Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood. 106:2854-61.2005

107) Oh H, Loberiza FR, Zhang M, Ringden O, Akiyama H, Asai T, Miyawaki S, Okamoto S, Horowitz MM, Antin JH, Bashey A, Bird JM, Carabasi MH, Fay JW, Gale RP, Giller RH, Goldman JM, Hale GA, Harris RE, Henslee-Downey J, Kolb HJ, Litzow MR, McCarthy PL, Neudorf SM, Sema DS, Tiberghien P, Barrett AJ. Comparison of graft-verrsus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood 2005;105:1408-1416.2005

108) Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y: KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood. 107(5):1806-1809. 2005

109) Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y, Kamijo T, Isoyama K, Kajiwara M, Sotomatsu M, Sugita K, Sugita K, Maeda M, Yabe H, Kinoshita A, Kaneko T, Hayashi Y, Ikuta K, Hanada R, Tsuchida M. :No advantage of dexamethasone over prednisolone for the outcome of standard-and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol. 23(27):6489-6498. 2005

110) Bessho F, Imashuku S, Hibi S, Tsuchida M, Nakahata T, Miyazaki S, Kojima S, Tsukimoto I, Hamajima N; Pediatric AA Follow-up Study Group in Japan. Serial morphologic observation of bone marrow in aplastic anemia in children. Int J Hematol. 81(5):400-404. 2005

111) 鎌田　薫（共編著）：民事法（全３巻）　日本評論社　2005

112) Kondo E, Akatsuka Y, Nawa A, Kuzushima K, Tsujimura K, Tanimoto M, Kodera Y, Morishima Y, Kuzuya K, Takahashi T: Retroviral vector backbone immunogenicity identification of cytotoxic T-cell epitopes in retroviral vector-packaging sequences. Gene Ther. 12(1):252-258,2005

113) Hashimoto D, Asakura S, Miyake S, Yamamura T, Van KL, Liu C, Tanimoto M, Teshima T: Stimulation of Host NKT Cells by Synthetic Glycolipid Regulates Acute Graft-versus-Host Disease by Inducing Th2 Polarization of Donor T Cells. J Immunol. 174(1):551-556.2005

114) Matsuoka K, Ichinohe T, Hashimoto D, Asakura S, Tanimoto M, Teshima T: Fetal tolerance to maternal antigens improves the outcome of allogeneic bone marrow transplantation by a CD4+ CD25+ T-cell-dependent mechanism. Blood. 107(1):404-409.2006.1

115) Shibakura M, Niiya K, Niiya M, Asaumi N, Yoshida C, Nakata Y, Tanimoto M: Induction of CXC and CC chemokines by all-trans retinoic acid in acute promyelocytic leukemia cells. Leuk Res. 29(7):755-759,2005

116) Matsuo Y, Drexler HG, Harashima A, Okochi A, Kojima K, Asakura S, Tanimoto M, Orita K: Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes. Leuk Res. 29(6):701-710,2005

117) Teshima T, Matsuo K, Matsue K, Kawano F, Taniguchi S, Hara M, Hatanaka K, Tanimoto M, Harada M, Nakao S, Abe Y, Wake A, Eto T, Takemoto Y, Imamura M, Takahashi S, Ishida Y, Kanda Y, Kasai M, Takaue Y: Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic

haematopoietic stem cell transplantation from related donors. Br J Haematol. 130(4):575-587,2005

118) Harashima A, Matsuo Y, Drexler HG, Okochi A, Motoda R, Tanimoto M, Orita K: Transcription factor expression in B-cell precursor-leukemia cell lines: preferential expression of T-bet. Leuk Res. 29(7):841-848,2005

119) Matsuoka K, Ichinohe T, Hashimoto D, Asakura S, Tanimoto M, Teshima T: Fetal tolerance to maternal antigens improves the outcome of allogeneic bone marrow transplantation by a CD4+CD25+ T cell-dependent mechanism. Blood. 107(1):404-409,2006

120) Yoshida I, Matsuo K, Teshima T, Hashimoto D, Tanimoto Y, Harada M, Tanimoto M: Transient respiratory disturbance by granulocyte-colony-stimulating factor administration in healthy donors of allogeneic peripheral blood progenitor cell transplantation. Transfusion. 46(2):186-192,2006

121) 沼澤理絵 中尾康夫 他：ダイアライザーのアルブミン漏出量の違いがグリコアルブミン値に及ぼす影響 日本透析医学会雑誌 38(8): 1391-1395, 2005

2. 学会発表

1) 西村美樹、小澤真一、丸田壱郎、中世古知昭、趙 龍桓、坂巻 壽、佐尾 浩、森 慎一郎、岡本真一郎、宮村耕一、森島泰雄、川瀬孝和、加藤俊一、小寺良尚：JMDP を介した UBMT5,660 例における慢性 GVHD の解析 第 67 回日本血液学会総会・第 47 回日本臨床血液学会総会 横浜 2005.9

2) 小島勢二、矢部普正、加藤俊一、加藤剛二、坂巻 壽、気賀沢寿人、生田孝一郎、原 純一、土田昌宏、森島泰雄、小寺良尚：後天性再生不良性貧血に対する非血縁者間同種骨髄移植 —JMDP215 例の検討— 第 67 回日本血液学会総会・第 47 回日本臨床血液学会総会 横浜 2005.9

3) 鍬塚八千代、安田貴彦、高橋太郎、稲本賢弘、徳永正浩、大庭 拓、宮村耕一、小寺良尚：骨髄異形成症候群に対する同種造血幹細胞移植 61 例における細胞遺伝学的異常が移植成績に与える影響 第 67 回日本血液学会総会・第 47 回日本臨床血液学会総会 横浜 2005.9

4) 神田善伸、坂巻 壽、佐尾 浩、岡本真一郎、小寺良尚、田野崎隆二、笠井正晴、平岡 諦、高橋 聡、宮脇修一、川瀬孝和、森島泰雄、加藤俊一：非血縁者間骨髄移植において移植前処置が移植成績におよぼす影響の解析 第 67 回日本血液学会総会・第 47 回日本臨床血液学会総会 横浜 2005.9

5) 稲本賢弘、安田貴彦、鍬塚八千代、徳永正浩、大庭 拓、寺倉精太郎、村田 誠、宮村耕一、直江知樹、小寺良尚：Fludarabine と melphalan を用いた非血縁者間 RIST23 例の feasibility study 第 67 回日本血液学会総会・第 47 回日本臨床血液学会総会 横浜 2005.9

6) 安田貴彦、高橋太郎、鍬塚八千代、稲本賢弘、徳永正浩、大庭 拓、宮村耕一、小寺良尚：当院で経験した後天性血友病（第 8 インヒビター）の一例 第 67 回日本血液学会総会・第 47 回日本臨床血液学会総会 横浜 2005.9

7) Nakaseko C, Nishimura M, Ozawa S, Cho R, Ohwada C, Maruta A, Sakamaki H, Sao H, Mori S, Okamoto S, Miyamura K, Kato S, Kawase T, Morishima Y, Kodera Y.: Risk factors and outcome of chronic GVHD: Analysis of 5,660 patients undergoing unrelated bone marrow transplantation through the Japan Marrow Donor Program. 47th Annual Meeting of the American Society of Hematology.Atlanta.2005.12

8) Tsuchida M, Sao H, Sakamaki H, Kawa K,

Kanda Y, Kato K, Hara M, Ishii M, Kikuchi A, Okamura J, Maruta A, Takaue Y, Kasai M, Yabe H, Morishima Y, Kato S, Kodera Y.: Unrelated donor marrow transplantation for acute lymphoblastic leukemia in Japan. A Japan Marrow Donor Program experience between 1993 and 2003. 47th Annual Meeting of the American Society of Hematology.Atlanta.2005.12

9) Kodera Y, Kato S, Harada M, Shiobara S, Hamajima N Morishima Y, Tanimoto M, Asano S, Ikeda Y, Dohi H, Nakahata T, Imamura M, Kawa K, Takaue Y, Kanda Y, Ymamoto K, Favre G, Gratwohl A.: Sever adverse events of allogeneic related peripheral blood stem cell donors-results of nation-wide 3,262 consecutively and prospectively registered case-survey in Japan and of its comparison to the outcome of retrospective survey shared with EBMT for stem cell donors. 47th Annual Meeting of the American Society of Hematology.Atlanta.2005.12

10) Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H, Tsuchida M, Kato S, Morishima Y, Kodera Y.: Tacrolimus/Methotrexate (MTX) versus Cyclosprorine/MTX for graft-versus-host disease (GVHD) prophylaxis in patients with sever aplastic anemia (SAA) who received marrow transplantation from unrelated donors: Results of matched pair analysis. 47th Annual Meeting of the American Society of Hematology.Atlanta.2005.12

11) Atsuta Y, Suzuki R, Yamamoto K, Terakura S, Iida H, Kohno A, Naoe T, Sao H, Kodera Y, Morishima Y, Hamajima N, Morishita Y.: Chronic graft-versus-host disease after allogeneic bone marrow transplantation in Japan: Identification of risk factors and prognostication. 47th Annual Meeting of the American Society of Hematology.Atlanta.2005.12

12) Kojima S, Yabe H, Kato K, Kigasawa H, sakamaki H, Tsuchida M, Kato S, Morishima Y, Kodera Y.: Effects of HLA-C and HLA-DQB1 mismatching on outcome of unrelated donor marrow transplantation for patients with sever aplastic anemia. 47th Annual Meeting of the American Society of Hematology. Atlanta.2005.12

13) Terakura S, Murata M, Nishida T, Emi N, Akatsuka Y, Riddell SR, Morishima Y, Kodera Y, Naoe T.: Increased risk for treatment-related mortality of bone marrow transplantation in GSTM1-positive recipients. 47th Annual Meeting of the American Society of Hematology. Atlanta.2005.12

14) Kato K, Kanda Y, Eto T, Muta T, Gondo H, Utsunomiya A, Taniguchi S, Shibuya T, Kato S, Kodera Y, Harada M.: Unrelated bone marrow transplantation for adult T cell leukemia/ lymphoma: A study from the Japan Marrow Donor Program. 47th Annual Meeting of the American Society of Hematology. Atlanta.2005.12

15) Suzuki T, Kiyoi H, Ozeki K, Tomita A, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Naoe T.: Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. 47th Annual Meeting of the American Society of Hematology. Atlanta.2005.12

16) Miyawaki S, Hatsumi N, Tamaki T, Naoe T,

Ozawa K, Kitamura K, Karasuno T, Mitani K, Kodera Y, Yamagami T, Koga D.: Prognostic impact of the detection of the WT1 gene mRNA with peripheral blood in adult acute myeloid leukemia (AML). 47th Annual Meeting of the American Society of Hematology. Atlanta.2005.12

17) 稲本賢弘、伊藤雅文、安田貴彦、高橋太郎、鍬塚八千代、大庭　拓、宮村耕一、平林紀男、小寺良尚：同種造血幹細胞移植後に出現する stage 3 の皮疹に治療は必要か（後方視的解析）　第 28 回日本造血移植学会総会　東京　2006.2

18) 大庭　拓、平林紀男、伊藤雅文、藤野雅彦、榎本和義、安田貴彦、高橋太郎、鍬塚八千代、稲本賢弘、宮村耕一、小寺良尚：同種移植後における肝臓病理～障害パターンとその臨床意義の検討　第 28 回日本造血移植学会総会　東京　2006.2

19) 鬼塚真仁、岸　賢治、稲本賢弘、大庭　拓、宮村耕一、小寺良尚、堀田知光、猪子英俊：移植後肺合併症と遺伝子多型性　第 28 回日本造血移植学会総会　東京 2006.2

20) 安田貴彦、高橋太郎、鍬塚八千代、稲本賢弘、大庭　拓、宮村耕一、小寺良尚：当院における同種幹細胞移植後の早期中枢神経合併症の臨床的検討　第 28 回日本造血移植学会総会　東京　2006.2

21) 高橋太郎、安田貴彦、鍬塚八千代、稲本賢弘、大庭　拓、宮村耕一、小寺良尚、大橋春彦、杉浦　勇：夜間発作性血色素尿症（PNH）に対し、骨髄非破壊的前処置を用いた同種末梢血幹細胞移植を施行した一症例　第 28 回日本造血移植学会総会　東京　2006.2

22) 鍬塚八千代、安田貴彦、高橋太郎、稲本賢弘、大庭　拓、宮村耕一、伊藤雅文、小寺良尚：当院における遅発性非感染性肺合併症 31 例の後方視的検討　第 28 回日本造血移植学会総会　東京　2006.2

23) 寺倉精太郎、村田　誠、西田徹也、恵美宣彦、赤塚美樹、森島泰雄、小寺良尚、直江知樹：代謝酵素 GSTM 1 陽性患者に対する非血縁者間骨髄移植では治療関連死亡リスクが増加する　第 28 回日本造血移植学会総会　東京　2006.2

24) 鈴木律朗、鈴宮敦司、中村栄男、河　敬也、小寺良尚、押味和夫：NK 細胞系白血病リンパ腫に対する造血幹細胞移植　第 28 回日本造血移植学会総会　東京 2006.2

25) 徳永正浩、宮村耕一、大橋春彦、石和田稔彦、土屋　滋、寺倉精太郎、鍬塚八千代、稲本賢弘、大庭　拓、小寺良尚：骨髄非破壊的前処置を用いた非血縁者間同種骨髄移植が成功した白血球粘着不全の 1 例　第 28 回日本造血移植学会総会　東京.2006.2

26) 阿部大二郎、小澤真一、西村美樹、丸田壱郎、中世古知昭、趙　龍桓、坂巻　壽、佐尾　浩、森慎一郎、岡本真一郎、宮村耕一、川瀬孝和、森島泰雄、加藤俊一、小寺良尚：JMDP を介した UBMT における長期生存者の QOL　第 28 回日本造血移植学会総会　東京.2006.2

27) 小澤真一、西村美樹、丸田壱郎、中世古知昭、趙　龍桓、坂巻　壽、佐尾　浩、森慎一郎、岡本真一郎、宮村耕一、川瀬孝和、森島泰雄、加藤俊一、小寺良尚：JMDP を介した UBMT5,660 例における慢性 GVHD の解析　第 2 報　慢性 GVHD 発症例の予後因子　第 28 回日本造血移植学会総会　東京.2006.2

28) 神田善伸、坂巻　壽、佐尾　浩、岡本真一郎、小寺良尚、田野崎隆二、笠井正晴、平岡　諦、高橋　聡、宮脇修一、川瀬孝和、森島泰雄、加藤俊一：非血縁者間骨髄移植において移植前処置が移植成績におよぼす影響の解析　第 28 回日本造血移植学会総会　東京.2006.2

29) 山本一仁　日本造血細胞移植学会における臨床研究：学会が関与する臨床研究とその体制　学会シンポジウム「ＥＢＭの

確立、多施設臨床共同研究の現状」第 67 回日本血液学会・第 47 回日本臨床血液学会合同総会 2005.

30) Mori T, Nakazato T, Aisa Y, Yamazaki R, Ikeda Y, Okamoto S: Prophylaxis of graft-versus-host disease (GVHD) with tacrolimus and methotrexate after allogeneic bone marrow transplantation (BMT) from unrelated donor: impact of blood level of tacrolimus on the development of acute GVHD. The 2006 BMT Tandem Meetings. Honolulu, Hawaii, 2006.

31) Yamazaki R, Mori T, Nakazato T, Aisa Y, Ikeda Y, Okamoto S: Pharmacokinetics of oral tacrolimus in recipients of allogeneic hematopoietic stem cell transplantation. The 2006 BMT Tandem Meetings. Honolulu, Hawaii, 2006.

32) Kato J, Yokoyama K, Mori T, Tsukada Y, Chen C.K, Ikeda Y, Okamoto S: MCVAC regimen in autologous peripheral blood stem cell transplantation for high-risk diffuse large B cell lymphoma (DLBCL). The 2006 BMT Tandem Meetings. Honolulu, Hawaii, 2006.

33) 原田実根:九州大学病院における治験体制整備　治験体制整備支援事業活動実績報告書　東京都　2005.6

34) 原田実根:造血幹細胞移植から再生医療へ　宮崎県内科医会特別講演　2005.6

35) 原田実根:難治性自己免疫疾患に対する自己末梢血幹細胞移植　福岡労災保険指定病院協会学術講演　2005.7

36) 原田実根：Stem cell transplantation in adults　学術国際シンポジウム「免疫の進化」　東京都 2005.8

37) 原田実根:造血幹細胞移植における最近の取り組み　第 12 回岐阜血液疾患研究会特別講演岐阜市　2005.9

38) 原田実根:造血幹細胞移植における最近の取り組み　第 12 回奈良県血液研究会特別講演　奈良市　2005.10

39) Harada M, Tsukamoto H, Nagafuji K, Nakashima H, Horiuchi T: A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. The 10th congress of Asia-Pacific Bone Marrow Transplantation. Hangzhou, China. 2005.10

40) 原田実根:難治性自己免疫疾患に対する自己末梢血幹細胞移植　第 10 回中四国 ECT 研究会岡山市　2005.11

41) 原田実根：造血幹細胞移植の現状　第 33 回日本内科学会九州支部生涯教育講演会　2006.1 原田実根：難治性自己免疫疾患に対する自己末梢血幹細胞移植　第 25 回山陰リウマチ性疾患協会　松山市　2006.2

42) 原田実根：白血病医療のシンポ　平成 17 年度福岡県医師会福岡ブロック日医生涯教育講座福岡市　2006.3

43) Ichinohe T, Maruya E, Tamaki S, Mtsuo K, Ochiai N, Ozawa M, Akaza T, Kaida K, Shimazaki C, Kimura H, Ueda Y, Tanaka C, Sumikuma T, Oka K, Uoshima N, Yanagimachi M, Saji H. Develoment of HLA antibody after HLA-identical anf HLA-haploidentical hematopoietic stem cell transplantation. 14th International HLA & Immunogenetice Workshop, Melbourne, Australia, November 29-December 2, 2005.

44) Maruya E, Ichinohe T, Tamaki S, Ochiai N, Saji H. Correlation of interleukin-10 promoter polymorphism with severity of acute GVHD after an HLA-identical siblin donor hematopoietic stem cell transplantation in a Japanese population. 14th International HLA & Immunogenetice Workshop, Melbourne, Australia, November 29-December 2, 2005.

45) Maruya E, Ichinohe T, Kaida K, Kanegane H, Hirakubo Y, Tanaka Y, Ohota M, Saji H. Inherited and acquired HLA gene defect: implications for stem cell transplantation. 14th International HLA & Immunogenetice Workshop, Melbourne, Australia, November

29-December 2, 2005.

46) 一戸辰夫:HLA 不一致造血細胞移植における NIMA 効果の意義 第 67 回日本血液学会・第 47 回日本臨床血液学会合同シンポジウム 横浜 2005.9

47) 森尾友宏、青木由貴、磯田健志、富澤大輔、長澤正之、水谷修紀、馬場憲三、水上美樹、渡邊健、清水則夫：日和見感染症の的確な早期診断を目指した高感度迅速網羅的微生物検出システムの開発 第 108 回日本小児科学会学術集会 東京 2005.4

48) 清水則夫、水上美樹、渡辺健、熊谷麻理、森尾友宏、馬場憲三、山本興太郎、梶原道子：再生医療をサポートする網羅的ウィルス検査システムの開発 第 53 回日本輸血学会総会 2005.5

49) 富澤大輔、青木由貴、磯田健志、梶原道子、長澤正之、森尾友宏、水谷修紀：原発性免疫不全症に対する Reduced-intensity stem cell transplantation. 第 47 回小児血液学会 宇都宮 2005.11

50) 梶原道子、青木由貴、佐藤隆介、磯田健志、富澤大輔、今井耕輔、辻陽一郎、長澤正之、森尾友宏、野々山恵章、水谷修紀：原発性免疫不全症 30 例に対する造血細胞移植に関する臨床的検討 第 67 回日本血液学会総会・第 47 回日本臨床血液学会総会合同総会 横浜 2005.9

51) 森尾友宏、小野敏明、青木由貴、佐藤隆介、富澤大輔、長澤正之、水谷修紀、梶原道子、海老沢美穂、落合央、峯岸志津子、水上美樹、渡邊健、清水則夫、大隈一興、関根暉彬：高感度迅速網羅的ウィルス測定法による造血幹細胞移植前後の感染モニター 第 28 回日本造血移植学会総会 東京 2006.2

52) 鳥飼宏基、赤塚美樹、宮崎幹則、辻村朱音、伊藤嘉規、辻村邦夫、元吉和夫、森島泰雄、小寺良尚、葛島清隆、高橋利忠：HLA-A＊3101 及び A＊3303 拘束性の CTSH 遺伝子上の同一多型部位にコードだれる２つの新規マイナー組織適合抗原の同定 基盤的癌免疫研究会第 9 回総会 東京 2005.6

53) 森島聡子、赤塚美樹、那波明弘、清野 透、鳥飼宏基、伊藤嘉規、辻村邦夫、葛島清隆、高橋利忠:HPV16 型 E6 上の HLA-A24 拘束性 CTL エピトープの同定と bortezomib, INF-γの併用効果 基盤的癌免疫研究会第 9 回総会 東京 2005.6

54) . Ogawa S , Nanya Y, Nakazaki K, Zhang C, Baily DK, Kennedy GC, Power estimation of genome-wide association analysis of mHAs relevant to pathogenesis of GVHD in unrelated hematopoietic stem cell transplantation, Human Genome Meeting 2005, Kyoto, 2005.8

55) Nakazaki K, Nannya Y, Sanada, Hosoya N, Wang L, Hangaishi A, Chiba S, Bailey DK, Kennedy GC and Ogawa S, Human Genome Meeting 2005, Large-scale genotyping of over 100,000 single nucleotide polymorphisms and mesuring linkage disequilibrium in the Japanese population. Human Genome Meeting 2005, Kyoto, 2005.8

56) 池原 進:特別公演 難病の革新的治療法 —移植と再生を利用して— 第 4 回日本組織移植学会総会 2005.8

57) 池原 進:特別公演 難病の革新的治療法 —移植と再生を利用して— 第 67 回日本血液学会・第 47 回日本臨床血液学会合同シンポジウム 2005.9

58) Morishima Y.: Clinical significance of HLA alleles and KIR matching in patients transplanted non-T cell depleted marrow from unrelated donor. :Japan Marrow Donor Program. 14th International HLA and Immunogenetics Workshop. Nov. 2005. Melbourne Australia

59) Yamamoto K, Aoki M, Sasazuki T: Heterozygosities of 4703 microsatellite markers in the Japanese population. Human Genome Meeting.Kyoto.2005.4,

60) Aoki M, Yamamoto K, Sasazuki T:

Genome-wide scan for gastric cancer by affected sibpair method. Human Genome Meeting. Kyoto.2005.4

61) Furuno K, Hara T, Sasazuki T, Yamamoto K: Identification of a target gene of T-box transcription factor Tbet in Th1 cell by human CpG microarray. Human Genome Meeting. Kyoto.2005.4

62) Yamamoto K, Aoki M, Sasazuki T: Heterozygosities of 4867 microsatellite markers in the Japanese population. The 5th Annual Meeting of the East Asian Union of Human Genetics Societies. Okayama.2005.9

63) Ishii E, Ueda I, Yamamoto K, Horiuchi H, Shirakawa R, Ohga S, Furuno K, Ogata Y, Zaitsu M, Morimoto A, Hara T, Imashuku S, Sasazuki T, Yasukawa M.: Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and functions of cytotoxic T lymphocytes. 21th Annual Meeting of the Histiocyte Society. Vancouver.2005.9

64) Furuno K, Hara T, Sasazuki T, Yamamoto K: Transcriptional Cross Regulation between T-bet and Onecut2 in Type 1 Helper T Cell. International Cytokine Society Council. Seul.2005.10

65) Onizuka M, Ando K, Kishi K, Kawada H, Morishima Y, Hotta T, Inoko H: An Analysis of Angiotensin Converting Enzyme Gene Polymorphisms and Non-infectious Pulmonary Dysfunction after Hematopoietic Stem Cell Transplantation. The American Society of Hematology 47th Annual Meeting and Exposition. Atlanta. 2005

66) Onizuka M, Kishi K, Ando K, Hotta T, Miyamura K, Kodera Y, Suyun Li, Inoko H: Non-infectious Pulmonary Complication after Stem Cell Transplantation and Genetic Background. Asia and Pacific Bone Marrow Transplantation annual meeting.. Shanghai. 2005

67) 鬼塚真仁、岸賢治、安藤潔、堀田知光、猪子英俊、稲本賢弘、大庭拓、宮村耕一、小寺良尚. 移植後肺合併症と遺伝子多型性　第28回日本造血細胞移植学会総会　東京　2006

68) 屋部登志雄:造血幹細胞移植および輸血におけるNK細胞の役割　第23回日本輸血学会北陸支部総会特別講演　金沢　2005.11

69) 平安恒幸、徳永勝士、屋部登志雄:日本人集団における特徴的なLILRA3遺伝子の多型性　第35回日本免疫学会総会学術集会　横浜　2005.12

70) Terakura S, Murata M, Nishida T, Emi N, Akatsuka Y, Riddell SR, Morishima Y, Kodera Y, Naoe T.: Increased risk for treatment-related mortality of bone marrow transplantation in GSTM1-positive recipients. The 47th annual meeting of the American Society of Hematology, in Atlanta, Georgia. Abstract accepted for poster presentation. 2005.12

71) Terakura S, Murata M, Warren EH, Sette A, Naoe T, Riddell SR.: A single minor histocom-patibility antigen AELLNIPFLY encoded by UGT2B17 is presented by HLA-A*2902, B*4402 and B*4403. 2006 BMT Tandem Meetings, Honolulu. 2006.2

72) 寺倉精太郎, 村田　誠, 西田徹也, 恵美宣彦, Warren EH, Riddell SR, 直江知樹:HLA-B*4403上に提示されるUGT2B17遺伝子由来マイナー抗原の同定　第67回日本血液学会総会・第47回日本臨床血液学会総会・合同総会　横浜　2005.9

73) 寺倉精太郎, 村田　誠, 西田徹也, 恵美宣彦, 赤塚美樹, 森島泰雄, 小寺良尚, 直江知樹:代謝酵素GSTM1陽性患者に対する非血縁者間骨髄移植では治療関連死亡リスクが増加する　第28回日本造血細胞移植学会総会　東京　2006.2

74) Kato S for the Japan Cord Blood Bank Network (JCBBN): Clinical results of CBSCT in Japan. The 3rd Annual Meeting

of the Asian Hematolog Association. Jeju, August 18-20, 2005

75) 加藤 俊一:HLA 不適合造血幹細胞移植－生着不全、GVHD、感染症を乗り越えて－ 第 67 回日本血液学会総会 横浜 2005.9

76) Kato S for the Japan Cord Blood Bank Network: Cord blood transplantation and cord blood banking. XXXth World Congress of the International Society of Hematology. Istanbul. 2005.9-10

77) Kudo k, Kojima S, Tabuchi K, Ishii E, Yabe H, Tawa A, Imaizumi M, Hanada R, Hamamoto K, Kobayashi K, Morimoto A, Nakayama H, Tsuchiya S, Tsuchida M, Horibe K, Tsukimoto I (Intr. by Yamamoto K) : Results of the Japanese Childhood Acute Myeloid Leukemia 99 Protocol for Down Syndrome and Acute Myeloid Leukemia. Session Type: Oral Session. Annual Meeting of American Society of Hematology. Atlanta. 2005

78) Tsuchida M, Sao H, Sakamaki H, Kawa K, Kanda Y, Kato K, Hara M, Ishii M, Kikuchi A, Okamura J, Maruta A, Takaue Y, Kasai M, Yabe H, Morishima Y, Kato S, Kodera Y: Unrelated Donor Marrow Transplantation for Acute Lymphoblastic Leukemia in Japan. A Japan Marrow Donor Program Experience between 1993 and 2003. Session Type: Oral Session. 47th Annual Meeting of American Society of Hematology. Atlanta. 2005.12

79) Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H, Tsuchida M, Kato S, Morishima Y, Kodera Y: Effects of HLA-C and HLA-DQB1 Mismatching on Outcome of Unrelated Donor Marrow Transplantation for Patients with Severe Aplastic Anemia. Session Type: Oral Session. 47th Annual Meeting of American Society of Hematology. Atlanta. 2005.12

80) Manabe A, Ohara A, Ikuta K, Hanada R, Yabe H, Kinoshita A, Koike K, Okimoto Y, Noguchi Y, Kajiwara M, Takahashi H, Sugita K, Fukushima T, Isoyama K, Saito M, Kikuchi A, Ota S, Kumagai M, Hayashi Y, Saito T, Tsuchida M: The Effect of Early High Dose Ara-C in Children with High-Risk Acute Lymphoblastic Leukemia (ALL): Tokyo Children's Cancer Study Group (TCCSG) Study L99-15. Session Type: Poster Session 26-I. 47th Annual Meeting of American Society of Hematology. Atlanta. 2005.12

81) Ogawa C, Ohara A, Manabe A, Hanada R, Takahashi H, Koh K, Kajiwar M, Maeda M, Sugita K, Kikuchi A, Isoyama K, Noguchi Y, Saito M, Ota S, Fukushima T, Yabe H, Toyoda Y, Saito T, Tsuchida M: Treatment Outcome of Discontinued L-Asparaginase in Children with Standard-Risk Acute Lymphoblastic Leukemia: Tokyo Children's Cancer Study Group (TCCSG) Study L99-15. Session Type: Poster Session 36-I. 47th Annual Meeting of American Society of Hematology. Atlanta. 2005.12

82) Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M: Repetitive Cycles of High-Dose Cytarabine Are Effective for Childhood Acute Myeloid Leukemia (AML): Long Term Outcome of the Children with AML Treated on Two Consecutive Trials of Tokyo Children's Cancer Study Group. Session Type: Poster Session 46-I. 47th Annual Meeting of American Society of Hematology. Atlanta. 2005.12

83) ITsukimoto I, Tawa A, Hanada R, Tabuchi K, Kigasawa H, Tsuchiya S, Tsuchida M, Yabe H Nakayama H, Kudo K, Kobayashi R, Hamamoto K, Imaizumi M, Morimoto A, Horibe K: Excellent Outcome of Risk Stratified Treatment for Childhood Acute Myeloid Leukemia-AML99 Trial. For the

Japanese Childhood AML Cooperative Study Group. Session Type: Poster Session 47-I. 47th Annual Meeting of American Society of Hematology. Altlanta. 2005.12

84) Imaizumi M, Tawa A, Hanada R, Tsuchida M, Taguchi K, Kobayashi R, Morimoto A, Nakayama H, Hamamoto K, Kudo K, Yabe H, Kigasawa H, Horibe K, Tsuchiya S, Tsukimoto I: Improved Outcome of Combination Therapy with ATRA, Anthracyclines and Cytarabine, AML99-M3 Protocol, for Childhood Acute Promyelocytic Leukemia. Session Type: Poster Session 49-I. 47th Annual Meeting of American Society of Hematology. Atlanta. 2005.12

85) Yagasaki H, Yabe H, Ayukawa H, Noguchi Y, Ijichi O, Kobayashi R, Tsuchida M, Mugishima H, Ohara A, Morimoto A, Oga S, Bessho F, Nakahata T, Tsukimoto I, Kojima S: Prospective, Randomized, Multicenter Study Comparing Antithymocyte Globulin (ATG) Alone with ATG Plus Cyclosporine (CsA) for Treatment of Children with Nonsevere Aplastic Anemia (nSAA). Session Type: Poster Session 201-I. 47th Annual Meeting of American Society of Hematology. Atlanta. 2005.12

86) Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H, Tsuchida M, Kato S, Morishima Y, Kodera Y: Tacrolimus/Methotrexate (MTX) Versus Cyclosprorine/MTX for Graft-Versus-Host Disease (GVHD) Prophylaxis in Patients with Severe Aplastic Anemia (SAA) Who Received Marrow Transplantation from Unrelated Donors: Results of a Matched Pair Analysis. Session Type: Poster Session 2-II. 47th Annual Meeting of American Society of Hematology. Atlanta. 2005.12

87) Shimada A, Taki T, Tabuchi K, Taketani T, Hanada R, Tawa A, Tsuchida M, Horibe K, Tsukimoto I, Hayashi Y: Tandem Duplications of the FLT3 and MLL Are Independent Poor Prognostic Factors in Pediatric Acute Myeloid Leukemia. AML99 Study in Japan. Session Type: Poster Session 30-III. 47th Annual Meeting of American Society of Hematology. Atlanta. 2005.12

88) 土田昌宏、田渕健、気賀沢寿人、加藤剛二、小池健一、秋山祐一、生田孝一郎、東英一、堀越泰雄、河野嘉文、小島勢二、麦島秀雄、加藤俊一(小児血液学会造血細胞移植委員会):小児急性リンパ性白血病の移植成績:小児血液学会登録より 第28回日本造血細胞移植学会 東京 2006.2

89) Kataoka I, Ishimaru F, Ichimura K, Yoshino T, Tanimoto M: Aberrant expression of Ikaros induces T-cell leukemia/lymphoma in mice without wild-type allelic loss[PS]. 47th Annual Meeting of the American Society of Hematology. 2005.12.10(Atlanta)

90) Maeda Y, Teshima T, Hashimoto D, Tanimoto M, Reddy P: Homeostatic proliferation of donor T cells reduces their capacity for inducing acute graft-versus-host disease[PS]. 47th Annual Meeting of the American Society of Hematology. 2005.12.10(Atlanta)

91) Kubonishi S, Katayama Y, Yamaguchi S, Tamamura H, Fujii N, Watanabe T, Seisdedos FA), Ikeda K, Tanimoto M: Sulfated colomininc acid enhances CXCR4 function and promotes hematopoietic stem/progenitor egress from bone marrow[PS]. 47th Annual Meeting of the American Society of Hematology. 2005.12.10(Atlanta)

92) Namba N, Katayama Y, Shinagawa K, Tanimoto M: Potential involvement of chemokine fractalkine/CX3CL1 and CX3CR1high monocytes in chronic graft versus host disease[PS]. 47th Annual

Meeting of the American Society of Hematology. 2005.12.10(Atlanta)

93)Matsuoka K, Ichinohe T, Asakura S, Hashimoto D, Tanimoto M, Teshima T: Fetal tolerance to maternal antigens improves the outcome of allogeneic bone marrow transplantation by a CD4+CD25+ T cell-dependent mechanism. 47th Annual Meeting of the American Society of Hematology. 2005.12.12(Atlanta)

94)Sakoda Y, Hashimoto D, (Takeuchi K), Asakura S, Akashi K, Tanimoto M, Harada M, Teshima T: Impaired thymic negative selection causes chronic graft-versus-host disease after allogeneic bone marrow transplantation. 47th Annual Meeting of the American Society of Hematology. 2005.12.12(Atlanta)

H．知的財産権の出願・登録状況（予定を含む）

１．特許取得、２．実用新案登録

・赤塚美樹：

1)Cathepsin H タンパク質由来の CD8+ 細胞傷害性 T リンパ球 mHA エピトープペプチドおよびその用途（申請中）特願 2004－325328

・森尾友宏：

1)造血幹細胞移植後の生着安定組成物、該組成物を得るためのキット、造血幹細胞移植後の生着安定方法、ならびにヒトモノクローナル抗体あるいはヒトポリクローナル抗体の製法（特願 2004－138468、出願日 H16.5.7）．出願人：黒岩保幸(株)リンフォテック．発明者：関根暉彬、森尾友宏、清水則夫他．

2)腫瘍・感染症および自己免疫疾患の予防・治療用 HLA 一致他人由来活性化リンパ球および該リンパ球を主成分とする製剤ならびに該製剤の製造方法、該製剤調製用キット（特開 2004-2312）出願人：黒岩保幸(株)リンフォテック．発明者：関根暉彬、森尾友宏、清水則夫他．

3)標的核酸の検出法（特願 2003-164799）出願人：清水則夫．発明者：関根暉彬、黒岩保幸、森尾友宏他．

4)臍帯血由来活性化リンパ球及び該リンパ球を主成分とする製剤ならびに該製剤の製造方法、該製剤調製用キット（特開 2002－171966）出願人：黒岩保幸(株)リンフォテック．発明者：関根暉彬、森尾友宏、清水則夫他．

・池原　進：

1）A Method of Inducing Immunological Tolerance. 特開 2001－172188　特願 09－531891

2) 骨髄液採取セット及び骨髄針　特願 2001－241586 平成 13 年 8 月 9 日(未)
権利者名：(株) 日本抗体研究所

2）悪性腫瘍の治療方法
特願 2003－49198
平成 15 年 2 月 26 日（未）
権利者名：関西 TLO（株）

３．その他

なし

Ⅲ.　分担研究報告書

Ⅲ.　テーマ－Ⅰ

細胞治療とその適正運用

厚生労働科学研究費補助金（ヒトゲノム・再生医療等研究事業）
分担研究報告書
「造血細胞移植療法総体の効率的かつ適正な運用とドナーの安全確保に関する研究」
分担研究者　小寺良尚　名古屋第一赤十字病院　造血細胞移植センター長

研究要旨：日本造血細胞移植学会との共同作業により、血縁造血幹細胞（骨髄・末梢血）ドナー事前登録・急性期有害事象報告・年次ドナー状況問い合わせ（同意が得られたドナーを対象に5年間）をセットにした血縁造血幹細胞ドナーフォローアップ事業を2005年4月より開始し、2006年3月からはこの事前登録と学会による適格性判定を加入条件としたドナー傷害保険を設定した。1年間のフォローアップの結果、わが国の血縁ドナーにおける骨髄：末梢血提供比率は約1：2であり、急性期有害事象報告は末梢血に多いものの重篤なものは発生していないことが示され、事前登録制が血縁ドナーにおける重篤有害事象を抑止する効果があることを推測させた。

A．研究目的

同種造血幹細胞移植は健常ドナーが幹細胞提供後も完全な健康状態を維持できることを前提としている。健常ドナーの内、血縁末梢血幹細胞ドナーについては今までも日本造血細胞移植学会によって、非血縁骨髄ドナーについては骨髄移植推進財団によって、又、臍帯血ドナーについては日本さい帯血バンクネットワークによって、提供後のフォローアップが行われてきたが、唯一血縁骨髄ドナーだけはその歴史の古さ故にフォローアップシステムが無く、ドナーが真に提供後も健康状態を維持しているかどうか確かめる術が無かった。一部に血縁骨髄ドナーが提供後の後遺症に悩んでいるといった話を聞くにつけ、更には他の血縁臓（肝、腎等）提供者において比較的重篤な後遺症が発生しているとの報告を見るにつけ、血縁骨髄ドナーのための提供後の健康把握システムが無いことはもはや看過すべきではないと考え、日本造血細胞移植学会との共同作業として新たに血縁造血幹細胞（骨髄・末梢血）ドナーフォローアップ 事業を開始した。

B．研究方法

調査対象は2005年4月1日以降に造血幹細胞採取が行われたすべての血縁ドナーとし、重点調査項目は2005年4月1日以降に登録された血縁造血幹細胞採取後 30 日以内における重篤有害事象発生状況の把握と、上記の血縁ドナーのうち、調査協力の同意が得られたドナーを対象とした造血幹細胞提供後 5 年間の中長期的な安全性の確認を、郵送により調査するシステムを構築した（図-1)。システムの開始にあたり１）日本造血幹細胞移植学会ドナー委員会からの手紙、２）血縁造血幹細胞ドナーフォローアップ事業－実施要綱－、３）血縁造血幹細胞ドナー登録票を、同種造血幹細胞採取実施の可能性のある約 2,000 診療科に郵送した。

C．研究結果

2005年4月から2006年4月末までの13ヶ月の事前登録数は705例で、骨髄提供：242例、末梢血提供：463例（骨髄：末梢血